New brain tumor scan could sharpen treatment decisions
NCT ID NCT06667726
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This phase 2 trial at Mayo Clinic is testing whether adding an amino acid PET/CT scan (using a radioactive tracer called FDOPA) to standard imaging can improve clinical management for people with brain tumors. The study will enroll 47 adults with brain tumors to see if the extra scan changes treatment plans in over half of cases. Researchers will also track side effects and whether the scan finds tumors outside standard MRI areas.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT BRAIN NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fluorodopa F 18 (18F-DOPA)
What this could lead to
If successful, this imaging technique could help doctors better plan treatment for brain tumors, such as surgery or radiation, and more accurately distinguish tumor growth from treatment side effects.
What could go wrong
This is a small, early-phase trial with only 47 participants, so results may not apply to everyone. The scan involves a radioactive tracer, though doses are very low.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.